Physician profile
Mary W Schofield
NPI 1346221892
$1,221.32
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $149 · 2021: $147 · 2022: $382 · 2023: $32.19 · 2024: $64.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $215.60 | 2021-2024 | Qelbree |
| Glaxosmithkline, LLC. | $211.33 | 2019-2022 | |
| Neos Therapeutics, LP | $180.80 | 2019-2022 | |
| Pfizer INC. | $144.36 | 2019-2022 | |
| Tris Pharma INC | $111.26 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $95.92 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $83.45 | 2019-2022 | |
| Cranial Technologies, INC | $28.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.43 | 2020-2022 | |
| Genentech USA, INC. | $23.38 | 2019 | |
| Sobi, INC | $23.21 | 2022 | |
| Merck Sharp & Dohme LLC | $16.57 | 2020 | |
| Verrica Pharmaceuticals INC. | $16.08 | 2024 | Ycanth |
| Novartis Pharmaceuticals Corporation | $15.22 | 2019 | |
| Adlon Therapeutics L.P. | $14.91 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Schofield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.